H.C. Wainwright Maintains a Buy Rating on TG Therapeutics (TGTX)

By Jason Carr

In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on TG Therapeutics (TGTXResearch Report), with a price target of $20. The company’s shares opened today at $8.17.

White said:

“Our $20 price target is based on the net present value of our revenue forecast through 2027, applying a 40% probability of success (POS) for ublituximab in CLL, a 40% POS for umbralisib in CLL, a 30% POS for ublituximab in NHL, a 35% POS for umbralisib in 40% POS for ublituximab in MS.”

According to TipRanks.com, White is a 5-star analyst with an average return of 14.7% and a 48.4% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Aileron Therapeutics Inc.

Currently, the analyst consensus on TG Therapeutics is a Strong Buy with an average price target of $15, an 83.6% upside from current levels. In a report issued on March 29, Cantor Fitzgerald also assigned a Buy rating to the stock with a $17 price target.

See today’s analyst top recommended stocks >>

Based on TG Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $53.86 million. In comparison, last year the company had a GAAP net loss of $41.53 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib.